For decades, PCOS (Polycystic Ovary Syndrome) has been a familiar term in women’s health, but for all the wrong reasons. By fixating on the ovaries, the name painted an incomplete picture, leaving millions of women confused, misdiagnosed, and cycling through specialists without real answers.
In May 2026, that finally changed.
The change emerged from a 14-year global consensus process that united over 22,000 patients, healthcare professionals, and researchers across six continents. The global medical community officially renamed the condition Polyendocrine Metabolic Ovarian Syndrome (PMOS).
But why was the name overhauled, and what does this shift mean for the millions of women navigating this condition?
This blog explains the problem with the old name, what PMOS means, a global consensus, the challenges, and the solutions.
The Problem with the Old Name
The term “polycystic ovary syndrome” traces back to 1935, when the condition (then called Stein-Leventhal syndrome) was first described and believed to originate purely in the ovaries. The name stuck for nearly a century, but it was misleading for several reasons:
- “Polycystic” implies cysts, but what appears on an ultrasound are actually small follicles (immature, fluid-filled sacs), not pathological cysts. A related study conducted as part of the renaming process confirmed there is no increased occurrence of abnormal ovarian cysts in the condition. Many women with PMOS never develop true cysts at all.
- The name focused on a single ovarian feature that isn’t the most clinically significant part of the condition for most women.
- It obscured the condition’s whole-body nature. PMOS is not just a gynecological issue; it’s a metabolic and endocrine disorder that affects insulin regulation, weight, blood sugar, cardiovascular health, and mental health, alongside the reproductive system.
What PMOS Actually Means
The new name reflects what the condition truly is:
- Poly: Multiple body systems involved
- Endocrine: Hormonal disturbances affecting insulin, androgens, and reproductive hormones
- Metabolic: Insulin resistance, diabetes risk, cardiovascular implications
- Ovarian: Acknowledging the reproductive aspects without making them the sole focus
- Syndrome: a collection of features that vary from person to person
As the researchers behind the change put it, putting “endocrine” and “metabolic” in the name tells clinicians this is a whole-body condition, not just a gynaecologic diagnosis.
A Global Consensus
Patients and clinicians overwhelmingly supported the change. Global surveys gathering over 14,000 responses from patients and health professionals found that 86% of patients and 71% of health professionals favored a new, symptom-based name over keeping “PCOS,” citing stigma, confusion, delayed diagnosis, and fragmented care as central problems.
Important to note: The diagnostic criteria and treatment protocols remain unchanged. During a three-year transition period, both “PCOS” and “PMOS” will appear side-by-side, with full integration into the International Evidence-Based Guideline (used across 195 countries) targeted for 2028.
The Challenges: Why Awareness Matters
PMOS affects roughly 1 in 8 women worldwide, more than 170 million people, yet up to 70% remain undiagnosed. In India, the burden is even higher: estimates suggest up to 1 in 5 young women of reproductive age are affected, well above the global average.
1. Delayed Diagnosis
Women with PMOS often spend years seeking answers. Global research shows that roughly a third of women see three or more health professionals over more than two years before receiving a diagnosis. Studies focused specifically on Indian women report a similar pattern, around a year’s delay in seeking help, followed by several more months before diagnosis is confirmed. Many women describe the process as frustrating, invalidating, and emotionally exhausting.
2. Fragmented Care
Because the old name suggested a purely gynecological issue, women often received fragmented care, seeing a dermatologist for acne, a GP for irregular periods, and a fertility specialist for infertility, without anyone connecting the underlying metabolic picture.
3. Metabolic Risks Overlooked
The old name skewed attention toward reproductive concerns at the expense of lifelong metabolic risk. Indian clinical data show that a significant share of women with PMOS also have non-alcoholic fatty liver disease and meet criteria for metabolic syndrome, risks that are often only caught when a clinician actively screens for them, rather than relying on visible weight changes.
4. Stigma and Mental Health
The stigma tied to a condition long framed around reproduction and appearance has taken a real toll on mental health. Indian studies consistently find that the psychological domain is the most affected aspect of quality of life for women with the condition; anxiety and low mood are common and often go unaddressed because appointments focus on cycles and fertility instead.
5. India’s Unique Challenge
India faces additional hurdles: uneven access to gynecologists and endocrinologists outside major cities, and an awareness gap between urban and rural populations. A large multi-site Indian study found PMOS prevalence ranging from roughly 7% to nearly 20%, depending on the diagnostic criteria used, with the highest rates in central and north India, and researchers point to India’s already-high burden of insulin resistance and type 2 diabetes as a major contributing factor.
The Solutions
For Individuals
1. Know the Symptoms
PMOS looks different in every woman, but common signs include:
- Irregular or absent periods
- Acne, unwanted facial/body hair, or scalp hair thinning
- Difficulty getting pregnant
- Unexplained weight gain or difficulty losing weight
- Mood changes, anxiety, or low mood
2. Prioritize Lifestyle Changes
Lifestyle modification is considered the first-line management approach in international guidelines, because insulin resistance sits at the center of the condition for most women.
Key strategies include:
- Eating to manage insulin resistance: Build meals around lean protein, high-fiber vegetables, healthy fats, and low-glycaemic carbohydrates, and avoid long gaps between meals.
- Exercising strategically: Strength training is particularly effective for improving insulin sensitivity, alongside regular aerobic activity like brisk walking or cycling.
- Managing stress and sleep: Both play a measurable role in insulin regulation and symptom severity.
3. Seek Comprehensive Care
Look for healthcare providers who treat PMOS as a whole-body condition, not just a reproductive issue. Ask about metabolic screening and don’t hesitate to raise mental health concerns; they’re part of the condition, not separate from it.
For Healthcare Providers
- Update terminology and help colleagues understand the shift in framing
- Screen for metabolic risk in all women with PMOS, regardless of body weight
- Ask about mental health proactively rather than waiting for patients to raise it
- Adopt a multidisciplinary approach, coordinating across gynecology, endocrinology, and dermatology where needed.
How Blumen Can Help
Blumen BioVitals has a wide range of products in its portfolio having nutraceuticals for women’s health.
At Blumen, we understand that managing PMOS requires a holistic approach, one that addresses not just reproductive health but the metabolic and hormonal imbalances at the core of the condition.
Our BLM OvaVital is an Inositol-based, non-hormonal nutraceutical formulated to support hormonal balance and metabolic health in PMOS, combining inositol, vitamin D, and green tea extract to support insulin sensitivity, menstrual regularity, and oxidative stress reduction. Learn more about BLM OvaVital here
Looking Ahead
The renaming of PCOS to PMOS is more than a change in terminology; it’s a shift in how the medical community understands and treats this condition. Language matters in medicine: the previous name often led to misconceptions and stigma, and this change helps move the conversation toward whole-body health rather than a single visible feature.
